Cargando…

Solubilization and Humanization of Paraoxonase-1

Paraoxonase-1 (PON1) is a serum protein, the activity of which is related to susceptibility to cardiovascular disease and intoxication by organophosphorus (OP) compounds. It may also be involved in innate immunity, and it is a possible lead molecule in the development of a catalytic bioscavenger of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarkar, Mohosin, Harsch, Christina Keventzidis, Matic, George T., Hoffman, Kathryn, Norris, Joseph R., Otto, Tamara C., Lenz, David E., Cerasoli, Douglas M., Magliery, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376767/
https://www.ncbi.nlm.nih.gov/pubmed/22720164
http://dx.doi.org/10.1155/2012/610937
_version_ 1782235865083281408
author Sarkar, Mohosin
Harsch, Christina Keventzidis
Matic, George T.
Hoffman, Kathryn
Norris, Joseph R.
Otto, Tamara C.
Lenz, David E.
Cerasoli, Douglas M.
Magliery, Thomas J.
author_facet Sarkar, Mohosin
Harsch, Christina Keventzidis
Matic, George T.
Hoffman, Kathryn
Norris, Joseph R.
Otto, Tamara C.
Lenz, David E.
Cerasoli, Douglas M.
Magliery, Thomas J.
author_sort Sarkar, Mohosin
collection PubMed
description Paraoxonase-1 (PON1) is a serum protein, the activity of which is related to susceptibility to cardiovascular disease and intoxication by organophosphorus (OP) compounds. It may also be involved in innate immunity, and it is a possible lead molecule in the development of a catalytic bioscavenger of OP pesticides and nerve agents. Human PON1 expressed in E. coli is mostly found in the insoluble fraction, which motivated the engineering of soluble variants, such as G2E6, with more than 50 mutations from huPON1. We examined the effect on the solubility, activity, and stability of three sets of mutations designed to solubilize huPON1 with fewer overall changes: deletion of the N-terminal leader, polar mutations in the putative HDL binding site, and selection of the subset of residues that became more polar in going from huPON1 to G2E6. All three sets of mutations increase the solubility of huPON1; the HDL-binding mutant has the largest effect on solubility, but it also decreases the activity and stability the most. Based on the G2E6 polar mutations, we “humanized” an engineered variant of PON1 with high activity against cyclosarin (GF) and found that it was still very active against GF with much greater similarity to the human sequence.
format Online
Article
Text
id pubmed-3376767
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33767672012-06-20 Solubilization and Humanization of Paraoxonase-1 Sarkar, Mohosin Harsch, Christina Keventzidis Matic, George T. Hoffman, Kathryn Norris, Joseph R. Otto, Tamara C. Lenz, David E. Cerasoli, Douglas M. Magliery, Thomas J. J Lipids Research Article Paraoxonase-1 (PON1) is a serum protein, the activity of which is related to susceptibility to cardiovascular disease and intoxication by organophosphorus (OP) compounds. It may also be involved in innate immunity, and it is a possible lead molecule in the development of a catalytic bioscavenger of OP pesticides and nerve agents. Human PON1 expressed in E. coli is mostly found in the insoluble fraction, which motivated the engineering of soluble variants, such as G2E6, with more than 50 mutations from huPON1. We examined the effect on the solubility, activity, and stability of three sets of mutations designed to solubilize huPON1 with fewer overall changes: deletion of the N-terminal leader, polar mutations in the putative HDL binding site, and selection of the subset of residues that became more polar in going from huPON1 to G2E6. All three sets of mutations increase the solubility of huPON1; the HDL-binding mutant has the largest effect on solubility, but it also decreases the activity and stability the most. Based on the G2E6 polar mutations, we “humanized” an engineered variant of PON1 with high activity against cyclosarin (GF) and found that it was still very active against GF with much greater similarity to the human sequence. Hindawi Publishing Corporation 2012 2012-06-07 /pmc/articles/PMC3376767/ /pubmed/22720164 http://dx.doi.org/10.1155/2012/610937 Text en Copyright © 2012 Mohosin Sarkar et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Sarkar, Mohosin
Harsch, Christina Keventzidis
Matic, George T.
Hoffman, Kathryn
Norris, Joseph R.
Otto, Tamara C.
Lenz, David E.
Cerasoli, Douglas M.
Magliery, Thomas J.
Solubilization and Humanization of Paraoxonase-1
title Solubilization and Humanization of Paraoxonase-1
title_full Solubilization and Humanization of Paraoxonase-1
title_fullStr Solubilization and Humanization of Paraoxonase-1
title_full_unstemmed Solubilization and Humanization of Paraoxonase-1
title_short Solubilization and Humanization of Paraoxonase-1
title_sort solubilization and humanization of paraoxonase-1
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376767/
https://www.ncbi.nlm.nih.gov/pubmed/22720164
http://dx.doi.org/10.1155/2012/610937
work_keys_str_mv AT sarkarmohosin solubilizationandhumanizationofparaoxonase1
AT harschchristinakeventzidis solubilizationandhumanizationofparaoxonase1
AT maticgeorget solubilizationandhumanizationofparaoxonase1
AT hoffmankathryn solubilizationandhumanizationofparaoxonase1
AT norrisjosephr solubilizationandhumanizationofparaoxonase1
AT ottotamarac solubilizationandhumanizationofparaoxonase1
AT lenzdavide solubilizationandhumanizationofparaoxonase1
AT cerasolidouglasm solubilizationandhumanizationofparaoxonase1
AT maglierythomasj solubilizationandhumanizationofparaoxonase1